Outcomes
EU-JAMRAI 2 Interim results
In this section, you will find the results, tools, guidelines, plans, and resources developed in EU-JAMRAI 2 to contribute to the challenge of antimicrobial resistance. As the project progresses and new materials are generated, the contents of this section will be updated, so we recommend consulting it periodically.
#EVALUATION
#SUSTAINABILITY
EU-JAMRAI 1 results
Policy briefs and recommendations
Pursuing efforts to tackle AMR at EU level: The Need for a second Joint Action on AMR and HAIs
Appropriate use of antibiotics in a One Health perspective
A policy brief that advocates for the importance of a holistic approach including targeted implementation strategies and time-appropriate surveillance in human and animal health.
The need to develop core elements at the European level on AMS and IPC
The need to develop indicators and targets for AMR action plans in the EU
A policy brief that urges the European Commission to establish indicators and targets to monitor the progress of the EU Action Plans, with a One Health perspective.
The need for a reinforced AMR One Health Network
This brief calls for an extension and strengthening of the AMR One Health Network mandate, to address all the components of this trans-sectoral and integrated approach and obtain a full impact of the EU action plan.
The urgent need to foster research on infection prevention and control to improve health security
Incentivizing antibiotic access and innovation
A policy brief developed in collaboration with Global R&D AMR Hub with the result of in-depth interviews with 13 countries pointing to a clear need for specific and detailed incentives.
European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet)
Understanding the use of evidence in health policymaking – case study: antibiotic prescribing guidelines
Improving access to essential antibiotics
Developed in collaboration with the EU Slovenian Presidency, this policy briefs presents three interventions, already with documented impact, needed to stimulate innovation and secure access to antibiotics.
